rs398122965
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM5PP3_ModeratePP5_Very_Strong
The NM_001199107.2(TBC1D24):c.724C>T(p.Arg242Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000018 in 1,613,996 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R242H) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001199107.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TBC1D24 | NM_001199107.2 | c.724C>T | p.Arg242Cys | missense_variant | 2/8 | ENST00000646147.1 | NP_001186036.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TBC1D24 | ENST00000646147.1 | c.724C>T | p.Arg242Cys | missense_variant | 2/8 | NM_001199107.2 | ENSP00000494678 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152228Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 249378Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135348
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461768Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 727198
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152228Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74368
ClinVar
Submissions by phenotype
DOORS syndrome Pathogenic:4Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant p.R242C in TBC1D24 (NM_001199107.2) has been reported previously in affected individuals with DOORS syndrome (Campeau PM et al). Functional studies reveal a damaging effect (Balestrini S et al). The variant has been submitted to ClinVar as Pathogenic. The p.R242C variant is observed in 1/15,478 (0.0065%) alleles from individuals of African background in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. There is a large physicochemical difference between arginine and cysteine, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. The p.R242C missense variant is predicted to be damaging by both SIFT and PolyPhen2. The arginine residue at codon 242 of TBC1D24 is conserved in all mammalian species. The nucleotide c.724 in TBC1D24 is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2014 | - - |
Pathogenic, no assertion criteria provided | literature only | Division of Medical Genetics; Sainte-Justine Hospital | Dec 22, 2014 | - - |
Pathogenic, criteria provided, single submitter | research | Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine | Jan 01, 2014 | We identified 26 families with DOORS syndrome; each patient had at least 3 of the 5 well-described features of DOORS syndrome, which include deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. A combination of whole-exome sequencing and Sanger sequencing identified homozygous or compound heterozygous pathogenic variants in TBC1D24 in 11 individuals from 9 families. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Developmental and epileptic encephalopathy, 16 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | May 10, 2021 | ACMG classification criteria: PS3 supporting, PS4 moderate, PM2 moderate, PM3 strong, PP3 supporting - |
Likely pathogenic, criteria provided, single submitter | clinical testing | NeuroMeGen, Hospital Clinico Santiago de Compostela | Jan 01, 2018 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 16, 2018 | The p.R242C pathogenic mutation (also known as c.724C>T), located in coding exon 1 of the TBC1D24 gene, results from a C to T substitution at nucleotide position 724. The arginine at codon 242 is replaced by cysteine, an amino acid with highly dissimilar properties. This mutation was identified in the homozgous and compound heterozygous states in multiple individuals with DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome) (Campeau PM et al. Lancet Neurol, 2014 Jan;13:44-58). Two cell lines expressing this mutation demonstrated shorter neurite length compared to wild type (Balestrini S et al. Neurology, 2016 Jul;87:77-85; Finelli MJ et al. Hum. Mol. Genet., 2018 Oct; doi.org/10.1093/hmg/ddy370). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
TBC1D24-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 20, 2023 | The TBC1D24 c.724C>T variant is predicted to result in the amino acid substitution p.Arg242Cys. This variant was reported in the compound heterozygous or homozygous state in multiple individuals with DOORS syndrome (Campeau et al. 2014. PubMed ID: 24291220; Balestrini et al. 2016. PubMed ID: 27281533; Fernández-Marmiesse et al. 2019. PubMed ID: 31780880). This variant is reported in 0.0065% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-2546873-C-T). This variant is interpreted as likely pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 03, 2024 | Published functional studies involving neuronal outgrowth assays of mouse cortical cells demonstrate a reduction in neurite length compared to wild-type (PMID: 27281533); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25169651, 24291220, 27281533, 28428906, 30579089, 31780880, 36147510, 31440721, 30335140) - |
Developmental and epileptic encephalopathy, 1;C3892048:Autosomal dominant nonsyndromic hearing loss 65;CN236805:Caused by mutation in the TBC1 domain family, member 24 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 242 of the TBC1D24 protein (p.Arg242Cys). This variant is present in population databases (rs398122965, gnomAD 0.007%). This missense change has been observed in individuals with autosomal recessive TBC1D24-related conditions (PMID: 24291220, 31780880). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 91395). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TBC1D24 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects TBC1D24 function (PMID: 27281533). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at